Preliminary study of two antiviral agents for hepatitis C genotype 1

New England Journal of Medicine

Volumn 366, Issue 3, 2012, Pages 216-224

  Lok, Anna S ^a   Gardiner, David F ^b   Lawitz, Eric ^d   Martorell, Claudia ^e   Everson, Gregory T ^f   Ghalib, Reem ^g   Reindollar, Robert ^h   Rustgi, Vinod ⁱ   McPhee, Fiona ^c   Wind Rotolo, Megan ^b   Persson, Anna ^b   Zhu, Kurt ^b   Dimitrova, Dessislava I ^b   Eley, Timothy ^b   Guo, Tong ^c   Grasela, Dennis M ^b   Pasquinelli, Claudio ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d Alamo Medical Research   (United States)

^e Research Institute   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g Texas Clinical Research Institute   (United States)

^h Carolinas Center for Liver Disease   (United States)

ⁱ Metropolitan Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASUNAPREVIR; DACLATASVIR; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADD ON THERAPY; ADULT; AGED; ANEMIA; ARTICLE; CHILL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG RESPONSE; DYSPNEA; FATIGUE; FEMALE; FEVER; GENOTYPE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; LEUKOPENIA; MALE; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SIDE EFFECT; TREATMENT DURATION; URINARY TRACT INFECTION; VIRUS MUTATION;

EID: 84856159009     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1104430     Document Type: Article

References (26)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-14. (Pubitemid 46780630)
2. Global alert and response (GAR): hepatitis C. Geneva: World Health Organization (http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/ index4.html).
3. The ABCs of hepatitis. Atlanta: Centers for Disease Control and Prevention (http://www.cdc.gov/hepatitis/Resources/Professionals/PDFs/ABCTable. pdf).
4. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-38. (Pubitemid 44307383)
5. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74.
6. Ghany M, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433-44.
7. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
8. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
9. Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010;138:108-15.
10. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93. [Erratum, N Engl J Med 2009;361:1027.]
11. Schiff E, Poordad F, Jacobson I, et al. Boceprevir (B) combination therapy in null responders (NR): response dependent on interferon responsiveness. J Hepatol 2008;48:Suppl 2:S46. abstract.
12. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28.
13. Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010;376:1467-75.
14. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010;465:96-100.
15. McPhee F. Identification and preclinical profile of the novel HCV NS3 protease inhibitor BMS-650032. J Hepatol 2010;52: Suppl 1:S296. abstract.
16. Nettles RE, Gao M, Bifano M, et al. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011;54:1956-65.
17. Pasquinelli C, Eley T, Villegas C, et al. Safety, tolerability, pharmacokinetics and antiviral activity following single- and multiple-dose administration of BMS-650032, a novel HCV NS3 inhibitor, in subjects with chronic genotype 1 HCV infection. Hepatology 2009;50:Suppl:411A. abstract.
18. Bifano M, Sevinsky H, Bedford BR, et al. Coadministration of BMS-790052 and BMS-650032 does not result in a clinically meaningful pharmacokinetic interaction in healthy subjects. Hepatology 2010;52: Suppl:719A. abstract.
19. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-26. (Pubitemid 36919874)
20. Poynard T, Imbert-Bismut F, Ratziu V, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 2002;9:128-33. (Pubitemid 36002476)
21. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003;38:481-92. (Pubitemid 36919870)
22. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
23. Zeuzem S, Buggisch P, Agarwal K, et al. Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PegIFN/RBV for up to 28 days in treatment naive, genotype 1 HCV subjects. Hepatology 2010;52:Suppl:400A-401A. abstract.
24. Zeuzem S, Asselah T, Angus PW, et al. Strong antiviral activity and safety of IFN-sparing treatment with the protease inhibitor BI 201335, the HCV polymerase inhibitor BI 207127 and ribavirin in patients with chronic hepatitis C. Hepatology 2010;52:Suppl:876A. abstract.
25. Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 in HCV genotype 1b-infected null responders. Hepatology 2011 October 10 (Epub ahead of print).
26. Bronowicki J-P, Pol S, Thuluvath PJ, et al. BMS-650032, an NS3 inhibitor, in combination with peginterferon alpha-2a and ribavirin in treatment-naive subjects with genotype 1 chronic hepatitis C infection. J Hepatol 2011;54:Suppl 1:S472. abstract.